Flavio Mantelli
Chief Medical OfficerDr. Flavio Mantelli, MD, PhD is Chief Medical Officer of OKYO Pharma Limited from February 10, 2026. In his new role at OKYO Pharma, Dr. Mantelli oversees the company's clinical development strategy, including the advancement of urcosimod in planned clinical trials for neuropathic corneal pain and additional orphan indications. Dr. Mantelli has unparalleled experience in ocular surface drug development, having led the clinical development, regulatory approval and global medical strategy of Oxervate (cenegermin-bkbj) at Domp farmaceutici S.p.A. Dr. Mantelli is a highly regarded ophthalmologist with an extensive background in cornea and ocular surface diseases, neurotrophic keratopathy and inflammatory eye conditions. He has critical knowledge and experience to OKYO in developing therapeutics from first-in-human studies through to global regulatory approval. As the clinical leader behind the transformation of a novel biologic into a first-in-class, FDA approved topical ophthalmic therapy, he set a new benchmark for orphan drug clinical development for treatments of corneal disease. Dr. Mantelli graduated in Medicine and Surgery summa cum laude from Universit Campus Bio-Medico of Rome, where he also completed his residency in ophthalmology and a PhD in regenerative medicine. He further pursued a postdoctoral fellowship in ocular surface glycobiology at the Schepens Eye Research Institute, Harvard Medical School. Dr. Mantelli joins OKYO Pharma from Domp where he served as the Chief Strategy &Innovation Officer, acting as the key link between the company and external partners, with the goal of promoting groundbreaking research initiatives and assessing new opportunities aligned with industry innovations. Previously he served as Chief Medical Officer and Head of R&D for the Ophthalmology and Neurotrophin platforms, leading all research and clinical development programs in ophthalmology. Prior to joining Domp, Dr. Mantelli researched the application of neurotrophins in ophthalmic and neurodegenerative diseases and was an adjunct associate professor of biology at Temple University in Philadelphia, PA. His professional experience includes positions at the IRCCS G.B. Bietti Foundation in Rome as a clinical scientist and as a consultant ophthalmologist at the Campus Biomedico University of Rome and the Cornea and Ocular Surface Unit of the Vita-Salute San Raffaele University of Milan. Graduating in Medicine and Surgery summa cum laude, Dr. Mantelli completed his residency program in ophthalmology and a PhD at the Campus Bio-Medico University of Rome. He also completed a postdoctoral fellowship in ocular surface glycobiology at the Schepens Eye Research Institute of Massachusetts Eye and Ear at Harvard Medical School in Boston.
Positions
- Company NameOKYO Pharma LimitedStock CodeOKYOPositionChief Medical OfficerColleagues
- RJRobert J. DempseyCEO & Executive Director
- GMGabriele Marco Antonio CerroneNon-Executive Chairman
- KSKeeren ShahChief Financial Officer
- RPRajkumar PatilChief Scientific Officer
- GSGary S. JacobChief Development Officer & Director
- WJWilly Jules SimonSenior Independent Non-Executive Director
- JPJohn Patrick BrancaccioIndependent Non-Executive Director
